CIK 0000875045
- Large accelerated filer
BIOGEN INC.
Sign in to watch- Ticker
- BIIB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330112644
- Phone
- +1 617-679-2000
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-02-23 | Clancy Paul J Executive VP and CFO | Shares withheld for taxes | −273 | $258.99 | $71K | 26,870 |
| 2016-02-23 | Clancy Paul J Executive VP and CFO | Exercise or conversion · Restricted Stock Unit | −579 | 4,611 | ||
| 2016-02-23 | Clancy Paul J Executive VP and CFO | Other disposition · Restricted Stock Unit | −1,149 | 3,462 | ||
| 2016-02-23 | COVINO GREGORY F VP, Chief Accounting Officer | Exercise or conversion | +66 | 2,708.97 | ||
| 2016-02-23 | COVINO GREGORY F VP, Chief Accounting Officer | Shares withheld for taxes | −22 | $258.99 | $6K | 2,686.97 |
| 2016-02-23 | COVINO GREGORY F VP, Chief Accounting Officer | Exercise or conversion · Restricted Stock Unit | −66 | 534 | ||
| 2016-02-23 | COVINO GREGORY F VP, Chief Accounting Officer | Other disposition · Restricted Stock Unit | −132 | 402 | ||
| 2016-02-23 | Artavanis-Tsakonas Spyridon SVP, Chief Scientific Officer | Exercise or conversion | +145 | 2,597.11 | ||
| 2016-02-23 | Artavanis-Tsakonas Spyridon SVP, Chief Scientific Officer | Shares withheld for taxes | −48 | $258.99 | $12K | 2,549.11 |
| 2016-02-23 | Artavanis-Tsakonas Spyridon SVP, Chief Scientific Officer | Exercise or conversion · Restricted Stock Unit | −145 | 1,155 | ||
| 2016-02-23 | Artavanis-Tsakonas Spyridon SVP, Chief Scientific Officer | Other disposition · Restricted Stock Unit | −287 | 868 | ||
| 2016-02-23 | ALEXANDER SUSAN H EVP, Chief Legal Officer | Exercise or conversion | +636 | 32,140 | ||
| 2016-02-23 | ALEXANDER SUSAN H EVP, Chief Legal Officer | Shares withheld for taxes | −300 | $258.99 | $78K | 31,840 |
| 2016-02-23 | ALEXANDER SUSAN H EVP, Chief Legal Officer | Exercise or conversion · Restricted Stock Unit | −636 | 5,064 | ||
| 2016-02-23 | ALEXANDER SUSAN H EVP, Chief Legal Officer | Other disposition · Restricted Stock Unit | −1,262 | 3,802 | ||
| 2016-02-23 | Cox John EVP Pharmaceutical Oper & Tech | Exercise or conversion | +810 | 30,898.39 | ||
| 2016-02-23 | Cox John EVP Pharmaceutical Oper & Tech | Shares withheld for taxes | −382 | $258.99 | $99K | 30,516.39 |
| 2016-02-23 | Cox John EVP Pharmaceutical Oper & Tech | Exercise or conversion · Restricted Stock Unit | −810 | 6,450 | ||
| 2016-02-23 | Cox John EVP Pharmaceutical Oper & Tech | Other disposition · Restricted Stock Unit | −1,608 | 4,842 | ||
| 2016-02-23 | Koppel Adam EVP, Strategy and Bus. Dev. | Exercise or conversion | +301 | 1,963.26 |
Page 71 of 73 · 1,456 trades